dots health software glp-1 habit tracker Weekly Injection Tracker: Medication & Weight Loss Log (PDF) Create this simple tracker and

Those who think transparency around medical decision-making is a baseline expectation will find Peak refreshing

Some individuals may also experience loss of appetite , fatigue , or mild stomach discomfort

PIONEER 7 investigators

[DOI] [PubMed] [Google Scholar] 66.Packer M, et al

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costsoften exceeding $1,000 per monthput them out of reach for many Americans whose insurance does not cover these medications